Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.

Autor: Fotia G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Saieva C; Cancer Risk Factors and Lifestyle Epidemiology Unit - ISPRO, Florence, Italy., Lee-Ying R; Department of Oncology, University of Calgary Tom Baker Cancer Centre, Tom Baker Cancer Centre, Calgary, Alberta, Canada., Patrikidou A; Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France., Nuzzo PV; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY., Zanardi E; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Rossetti S; IRCCS Istituto Nazionale dei Tumori Fondazione G. Pascale, Naples, Italy., Davidsohn M; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Eid M; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., El Zarif T; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., McClure H; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Spinelli GP; Division of Medical Oncology, Casa della Salute di Aprilia, Latina, Sapienza University of Rome, Italy., Damassi A; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Murianni V; Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Vauchier C; Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France., Oliveira TM; Instituto D'Or de Pesquisa e Ensino, Salvador, Brazil., Malgeri A; Fondazione Policlinico Campus Bio-Medico di Roma, Rome, Italy., Modesti M; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Mestre RP; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland., Valenca L; Instituto D'Or de Pesquisa e Ensino, Salvador, Brazil., Ravi P; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Santini D; Oncology Unit, Umberto I hospital, Rome, Italy., Pignata S; IRCCS Istituto Nazionale dei Tumori Fondazione G. Pascale, Naples, Italy., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy., Sweeney C; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia., Heng D; Department of Oncology, University of Calgary Tom Baker Cancer Centre, Tom Baker Cancer Centre, Calgary, Alberta, Canada., Procopio G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Russo A; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy., Francini E; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Electronic address: edoardo.francini@unifi.it.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Oct; Vol. 22 (5), pp. 102185. Date of Electronic Publication: 2024 Aug 09.

Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors.

Autor: Suzuki K; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Electronic address: pikataro1012@gmail.com., Shiraishi Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Furukawa J; Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan., Okamura Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Bando Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Hara T; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Okada K; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Terakawa T; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Hyodo Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Chiba K; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Teishima J; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Nakano Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan., Miyake H; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Oct; Vol. 22 (5), pp. 102140. Date of Electronic Publication: 2024 Jun 14.

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.

Autor: Vaz-Ferreira A; Oncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal., Tavares V; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/Pathology and Laboratory Medicine Department, Clinical Pathology SV/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto CCC), 4200-072 Porto, Portugal.; Faculty of Medicine of University of Porto (FMUP), 4200-072 Porto, Portugal.; ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal., de Melo IG; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/Pathology and Laboratory Medicine Department, Clinical Pathology SV/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto CCC), 4200-072 Porto, Portugal.; Faculty of Medicine of University of Porto (FMUP), 4200-072 Porto, Portugal., Rodrigues PR; Oncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal., Afonso A; Oncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal., Maurício MJ; Oncology Department, Portuguese Institute of Oncology of Porto (IPO Porto), 4200-072 Porto, Portugal., Medeiros R; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/Pathology and Laboratory Medicine Department, Clinical Pathology SV/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto CCC), 4200-072 Porto, Portugal.; Faculty of Medicine of University of Porto (FMUP), 4200-072 Porto, Portugal.; ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal.; Faculty of Health Sciences, Fernando Pessoa University, 4200-150 Porto, Portugal.; Research Department, Portuguese League Against Cancer (NRNorte), 4200-172 Porto, Portugal.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2024 Sep 12; Vol. 25 (18). Date of Electronic Publication: 2024 Sep 12.

Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.

Autor: Roubaud G; Department of Medical Oncology, Institut Bergonié, Bordeaux, France. Electronic address: g.roubaud@bordeaux.unicancer.fr., Attard G; University College London Cancer Institute, London, UK., Boegemann M; Department of Urology, Muenster University Hospital, Muenster, Germany; Westgerman Cancer Center, Münster, Germany., Olmos D; Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain., Trevisan M; Janssen EMEA, Geneva, Switzerland., Antoni L; Janssen Pharmaceutica NV, Beerse, Antwerp, Belgium., Pascoe K; Janssen Vaccines & Prevention B.V., Leiden, the Netherlands., Capone C; Janssen Pharmaceutica NV, Beerse, Antwerp, Belgium., Van Sanden S; Janssen Pharmaceutica NV, Beerse, Antwerp, Belgium., Hashim M; Janssen Vaccines & Prevention B.V., Leiden, the Netherlands., Palmer S; Centre for Health Economics, University of York, York, UK., Chi K; BC Cancer and Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Sep; Vol. 209, pp. 114183. Date of Electronic Publication: 2024 Jun 17.

Characterization and Prediction of Organic Anion Transporting Polypeptide 1B Activity in Prostate Cancer Patients on Abiraterone Acetate Using Endogenous Biomarker Coproporphyrin I.

Autor: Wang Z; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Luk KHY; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Cheong EJY; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Tham SM; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Periaswami R; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Toh PC; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Wang Z; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Wu QH; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Tsang WC; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Kesavan A; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Wong ASC; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Wong PT; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Lim F; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.)., Chiong E; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.) surce@nus.edu.sg phaccye@nus.edu.sg., Chan ECY; Department of Pharmacy and Pharmaceutical Sciences (Zite.W., K.H.Y.L., E.J.Y.C., E.C.Y.C.) and Department of Surgery, Yong Loo Lin School of Medicine (S.M.T., R.P., E.C.), National University of Singapore, Singapore; Department of Urology (P.C.T., Ziti.W., Q.H.W., W.C.T., A.K., E.C.) and Department of Pharmacy (P.T.W., F.L.), National University Hospital, National University Health System, Singapore; Department of Haematology-Oncology, National University Cancer Institute, Singapore (A.S.C.W.); and National University Cancer Institute, Singapore (P.T.W.) surce@nus.edu.sg phaccye@nus.edu.sg.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Oct 16; Vol. 52 (11), pp. 1356-1362. Date of Electronic Publication: 2024 Oct 16.